|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600126461 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-09 15:58:56 |
|
注册时间: Date of Registration: |
2026-06-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
椎管内硬膜外脊神经前根刺激技术治疗慢性脊髓损伤后下肢运动功能障碍 |
|
Public title: |
Epidural spinal nerve anterior root stimulation technique for the treatment of lower limb motor dysfunction after chronic spinal cord injury |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
椎管内硬膜外脊神经前根刺激技术治疗慢性脊髓损伤后下肢运动功能障碍 |
|
Scientific title: |
Epidural spinal nerve anterior root stimulation technique for the treatment of lower limb motor dysfunction after chronic spinal cord injury |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曹晓建 |
研究负责人: |
曹晓建 |
|
Applicant: |
Cao Xiaojian |
Study leader: |
Cao Xiaojian |
|
申请注册联系人电话: Applicant telephone: |
+86 25 6830 6300 |
研究负责人电话:
Study leader's |
+86 25 6830 6300 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xiaojiancao001@163.com |
研究负责人电子邮件: Study leader's E-mail: |
xiaojiancao001@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
|
Applicant address: |
300 Guangzhou Road, Gulou District, Nanjing City, Jiangsu Province |
Study leader's address: |
300 Guangzhou Road, Gulou District, Nanjing City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学第一附属医院(江苏省人民医院) |
||
|
Applicant's institution: |
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) |
||
|
研究负责人所在单位: |
南京医科大学第一附属医院(江苏省人民医院) |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-SR-892 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京医科大学第一附属医院(江苏省人民医院)伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People's Hospital) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-29 00:00:00 | ||
|
伦理委员会联系人: |
王悦 |
||
|
Contact Name of the ethic committee: |
Wang Yue |
||
|
伦理委员会联系地址: |
江苏省南京市鼓楼区广州路300号 |
||
|
Contact Address of the ethic committee: |
300 Guangzhou Road, Gulou District, Nanjing City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 6830 6360 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京医科大学第一附属医院(江苏省人民医院) |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市鼓楼区广州路300号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
300 Guangzhou Road, Gulou District, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金和社会赞助 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation and social sponsorship |
||||||||||||||||||||||
|
研究疾病: |
截瘫后下肢运动功能障碍 |
||||||||||||||||||||||
|
Target disease: |
Lower limb motor dysfunction after paraplegia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
治疗脊髓损伤后下肢运动功能障碍 |
||||||||||||||||||||||
|
Objectives of Study: |
Treatment of lower limb motor dysfunction after spinal cord injury |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 18岁-70岁; 2. 中枢性神经系统损伤后截瘫(ASIA A,B,C)、尤其是T10水平以上脊髓功能损伤; 3. 损伤时间在9个月以上,5年以内的患者; 4. 主要表现为双下肢运动及感觉功能障碍且经过前期阶梯治疗(如药物、物理治疗、介入性注射等)失败者; 5.下肢肌肉无明显萎缩,肌电图显示未见L2至S1下运动神经元损害表现。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged 18 to 70 years; 2. Paralysis following central nervous system injury (ASIA A, B, C), especially spinal cord injury above the T10 level; 3. Patients with injury duration of more than 9 months but within 5 years; 4. Mainly presenting with motor and sensory dysfunction in both lower limbs and having failed prior stepwise treatments (such as medication, physical therapy, interventional injections, etc.); 5. No significant atrophy of lower limb muscles, and electromyography shows no evidence of lower motor neuron damage from L2 to S1. |
||||||||||||||||||||||
|
排除标准: |
1.感染风险高:手术区皮肤感染、全身性感染或脊柱感染/肿瘤; 2.凝血障碍:血小板<50×10?/L、使用抗凝药未停药; 3.神经结构异常:椎管内占位(如肿瘤)或既往手术导致解剖变异; 4.严重系统性疾病:未控制的糖尿病、心脑血管病(脑梗死史、顽固性高血压)、肝肾功能衰竭、活动性消化道出血等; 5.神经系统合并症:癫痫、帕金森病、合并严重颅脑损伤、认知障碍(无法理解SCS操作设备,无法配合神经系统功能检查等); 6.免疫系统功能异常及缺陷。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. High risk of infection: skin infection at the surgical site, systemic infection, or spinal infection/tumor; 2. Coagulation disorders: platelets <50×10?/L, or use of anticoagulants not discontinued; 3. Abnormal neural structures: space-occupying lesions in the spinal canal (such as tumors) or anatomical variations caused by previous surgery; 4. Severe systemic diseases: uncontrolled diabetes, cardiovascular or cerebrovascular diseases (history of cerebral infarction, refractory hypertension), liver or kidney failure, active gastrointestinal bleeding, etc.; 5. Neurological comorbidities: epilepsy, Parkinson's disease, severe traumatic brain injury, cognitive impairment (unable to understand SCS operation equipment or cooperate with neurological function examination, etc.); 6. Immune system dysfunction and deficiencies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-15 00:00:00至 To 2029-06-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-15 00:00:00 至 To 2029-06-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后6个月,临床试验公共管理平台http://www.medresman.org.cn/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the end of the study, Clinical Trial Public Management Platform http://www.medresman.org.cn/ |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例数据采集表结合电子数据电子采集和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form (CRF) and Electronic Data Capture (EDC) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |